|Bid||322.20 x 1100|
|Ask||322.30 x 800|
|Day's range||318.50 - 341.55|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||38.30|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||349.33|
The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?
Authorization for Moderna's (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.